Shanghai Hile Bio-Technology Past Earnings Performance
Past criteria checks 4/6
Shanghai Hile Bio-Technology has been growing earnings at an average annual rate of 50.4%, while the Pharmaceuticals industry saw earnings growing at 10.1% annually. Revenues have been growing at an average rate of 2.6% per year. Shanghai Hile Bio-Technology's return on equity is 12.4%, and it has net margins of 70.3%.
Key information
50.4%
Earnings growth rate
51.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 2.6% |
| Return on equity | 12.4% |
| Net Margin | 70.3% |
| Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shanghai Hile Bio-Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 222 | 156 | 86 | 26 |
| 30 Jun 23 | 257 | 136 | 100 | 30 |
| 31 Mar 23 | 286 | 125 | 120 | 30 |
| 31 Dec 22 | 300 | 122 | 126 | 30 |
| 30 Sep 22 | 352 | 57 | 147 | 31 |
| 30 Jun 22 | 350 | 58 | 146 | 30 |
| 31 Mar 22 | 331 | 51 | 131 | 30 |
| 31 Dec 21 | 347 | 54 | 135 | 29 |
| 30 Sep 21 | 331 | 39 | 128 | 31 |
| 30 Jun 21 | 309 | 33 | 129 | 30 |
| 31 Mar 21 | 304 | 16 | 142 | 29 |
| 31 Dec 20 | 259 | 9 | 125 | 30 |
| 30 Sep 20 | 257 | -4 | 135 | 25 |
| 30 Jun 20 | 258 | -2 | 124 | 25 |
| 31 Mar 20 | 254 | 12 | 106 | 26 |
| 31 Dec 19 | 278 | 12 | 111 | 30 |
| 30 Sep 19 | 275 | -2 | 95 | 34 |
| 30 Jun 19 | 285 | 5 | 112 | 34 |
| 31 Mar 19 | 274 | 7 | 121 | 32 |
| 31 Dec 18 | 255 | 21 | 121 | 27 |
| 30 Sep 18 | 261 | 76 | 133 | 23 |
| 30 Jun 18 | 265 | 92 | 124 | 30 |
| 31 Mar 18 | 292 | 109 | 133 | 24 |
| 31 Dec 17 | 304 | 114 | 148 | 20 |
| 30 Sep 17 | 332 | 98 | 169 | 13 |
| 30 Jun 17 | 334 | 88 | 196 | 0 |
| 31 Mar 17 | 340 | 82 | 200 | 0 |
| 31 Dec 16 | 343 | 86 | 194 | 0 |
| 30 Sep 16 | 330 | 93 | 176 | 0 |
| 30 Jun 16 | 322 | 94 | 160 | 0 |
| 31 Mar 16 | 322 | 95 | 152 | 0 |
| 31 Dec 15 | 317 | 95 | 144 | 0 |
| 30 Sep 15 | 291 | 92 | 132 | 0 |
| 30 Jun 15 | 278 | 101 | 116 | 0 |
| 31 Mar 15 | 278 | 99 | 121 | 0 |
| 31 Dec 14 | 285 | 101 | 124 | 0 |
| 31 Dec 13 | 319 | 119 | 118 | 0 |
Quality Earnings: 603718 has a high level of non-cash earnings.
Growing Profit Margin: 603718's current net profit margins (70.3%) are higher than last year (16.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603718's earnings have grown significantly by 50.4% per year over the past 5 years.
Accelerating Growth: 603718's earnings growth over the past year (172.4%) exceeds its 5-year average (50.4% per year).
Earnings vs Industry: 603718 earnings growth over the past year (172.4%) exceeded the Pharmaceuticals industry 8.1%.
Return on Equity
High ROE: 603718's Return on Equity (12.4%) is considered low.